The company released those numbers after it was criticised earlier in the week by a US health agency for possibly including outdated information when it claimed 79% efficacy against symptomatic Covid. All the figures are based on a Phase 3 clinical trial done across the US, Chile, and Peru. While generally held in high regard by health authorities across the world, the AstraZeneca vaccine has been dogged by controversy – including fears that it may cause blood clots.
76% overall efficacy (⬇️ from 79%)100% efficacy against hospitalization/severe disease85% efficacy in >65No safety concerns (>32000 participants) Still looks good! Link: https://t.co/6T83uRJ5mB https://t.co/IlWRMjH6EF pic.twitter.com/aIQtfYV777 — Isaac Bogoch (@BogochIsaac) March 25, 2021 Those (blood clot) concerns caused a whole bunch of European countries – including France, Germany, and Spain – to temporarily stop using the vaccine, CNN said. They ultimately resumed usage after the European Union’s drug regulatory agency declared the vaccine to be safe, saying its benefits outweigh the risk. In Malaysia, the AstraZeneca vaccine has received conditional approval, with the government ordering 12.8 million doses, according to CodeBlue. Putrajaya is sticking with its purchase, convinced for now that the vaccine isn’t linked to blood clots, Bernama reported. Science, Technology, and Innovation Minister Khairy Jamaluddin previously said that the AstraZeneca vaccine would likely be administered in rural areas – as opposed to the Pfizer-BioNtech vaccine in urban centers. (Source: CNN [1] [2] [3], CodeBlue, Bernama. Header image: Olia Danilevich / Pexels.)
